GLP-1 drug interactions

GLP-1 Drug Interaction Checker

Search any medication to see how it interacts with Wegovy, Ozempic, Zepbound, Mounjaro, or Foundayo. Every entry is severity-tiered and cites the specific FDA prescribing-information section it comes from. Currently 18 verified interactions in the database.

Filter by severity

Showing 18 of 18 entries. Every entry cites its FDA prescribing information section. This tool is educational and does NOT replace your prescriber or pharmacist.

Other GLP-1 receptor agonists

GLP-1 receptor agonist

Serious — close monitoring

Common brand names

Wegovy · Ozempic · Rybelsus · Zepbound · Mounjaro · Foundayo · Saxenda · Victoza · Trulicity · Bydureon · Byetta

Clinical effect

Co-administration of two GLP-1 receptor agonists is not recommended per the Limitations of Use in Section 1 of the FDA Wegovy, Zepbound, and Foundayo labels. No studies have evaluated combined use, and the additive risks (GI side effects, hypoglycemia in T2D, pancreatitis) make combination therapy clinically unjustified.

What to do

Do not use two GLP-1 receptor agonists at the same time. Switch by stopping the first drug and starting the second at its lowest dose on the next scheduled injection day (the standard practical-clinical switching guidance). Note: this is the practical clinical-practice guidance based on next-dose-day switching. Full pharmacokinetic washout (5 half-lives, ~35 days for semaglutide, ~25 days for tirzepatide) is what our washout calculator at /tools/glp1-washout-calculator uses for surgery/pregnancy planning. The two different guidances apply to different clinical contexts.

Mechanism

Both drugs target the same GLP-1 receptor. Co-administration produces no additional efficacy but doubles the receptor activation, magnifying side effects.

Source: Wegovy PI Section 1 (Limitations of Use: concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended); Zepbound PI Section 1 (Limitations of Use); Foundayo PI Section 1 (Limitations of Use). Half-lives: semaglutide ~1 week (Wegovy PI Section 12.3), tirzepatide ~5 days (Zepbound/Mounjaro PI Section 12.3).

Insulin

Insulin (long, intermediate, or rapid acting)

Serious — close monitoring

Common brand names

Lantus · Toujeo · Basaglar · Tresiba · Levemir · Humalog · Novolog · Apidra · Fiasp · Lyumjev · Humulin · Novolin

Clinical effect

Concomitant use of insulin with a GLP-1 receptor agonist increases the risk of hypoglycemia (low blood sugar), including severe hypoglycemia.

What to do

Every GLP-1 label tells prescribers to consider reducing the insulin dose when the GLP-1 is started. The labels do not set a fixed percentage; your prescriber sets the reduction. Blood glucose should be monitored closely. Discuss the dose-reduction plan with your prescriber BEFORE the first GLP-1 dose.

Mechanism

GLP-1 receptor agonists enhance glucose-dependent insulin secretion and reduce glucagon. Adding exogenous insulin on top of this effect creates additive hypoglycemic risk.

Source: Wegovy PI Section 7.1; Ozempic PI Section 7.1; Mounjaro PI Section 7.1; Zepbound PI Section 7.1; Foundayo PI Section 7.2

Sulfonylureas

Sulfonylurea (oral diabetes medication)

Serious — close monitoring

Common brand names

Glucotrol · glipizide · DiaBeta · Glynase · Micronase · glyburide · Amaryl · glimepiride

Clinical effect

Combining a sulfonylurea with a GLP-1 receptor agonist substantially increases the risk of hypoglycemia.

What to do

If you are on a sulfonylurea (glipizide, glyburide, glimepiride), your prescriber should typically reduce the sulfonylurea dose when starting a GLP-1 receptor agonist. Some patients are tapered off the sulfonylurea entirely. Monitor blood glucose closely.

Mechanism

Sulfonylureas force insulin secretion regardless of glucose level. GLP-1 receptor agonists add a glucose-dependent insulin boost on top, producing additive hypoglycemia risk.

Source: Wegovy PI Section 7.1; Ozempic PI Section 7.1; Mounjaro PI Section 7.1; Zepbound PI Section 7.1; Foundayo PI Section 7.2 (insulin secretagogues)

CYP3A4 inhibitors and inducers (Foundayo only)

CYP3A4 inhibitor or inducer

Serious — close monitoring

Common brand names

ketoconazole · itraconazole · clarithromycin · ritonavir · cobicistat · grapefruit juice · rifampin · rifampicin · carbamazepine · phenytoin · St. John's Wort · efavirenz

Clinical effect

This interaction applies to FOUNDAYO (orforglipron) only — the injectable GLP-1s are peptides and are not affected. Foundayo is metabolized by CYP3A4, so strong CYP3A4 inhibitors raise Foundayo levels (clarithromycin raised Foundayo exposure 3.5-fold in the label's study), strong inhibitors that also block the OATP1B liver transporter are expected to raise it further, and strong CYP3A4 inducers can drop Foundayo levels enough to reduce its effectiveness (carbamazepine cut exposure 82%).

What to do

If you take FOUNDAYO with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin), do not exceed a Foundayo dose of 9 mg once daily. AVOID Foundayo with a strong CYP3A4 inhibitor that also inhibits OATP1B — the label's example is ritonavir; ask your pharmacist whether this applies to other boosted HIV or hepatitis regimens (e.g., cobicistat-containing). AVOID using Foundayo with a strong CYP3A4 inducer (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort). With a moderate CYP3A4 inducer (e.g., efavirenz), your prescriber should monitor Foundayo effectiveness and escalate the dose as needed. This does not apply to Wegovy, Ozempic, Mounjaro, or Zepbound.

Mechanism

Orforglipron is a small-molecule oral GLP-1 receptor agonist cleared primarily by CYP3A4. Inhibiting that enzyme increases orforglipron exposure; inducing it decreases exposure. Injectable GLP-1 peptides (semaglutide, tirzepatide) are not CYP-metabolized, so this interaction does not apply to them.

Source: Foundayo PI Sections 2.2 and 7.1 — strong CYP3A4 inhibitor: maximum Foundayo dose 9 mg once daily; strong CYP3A4 inhibitor that also inhibits OATP1B (e.g., ritonavir): avoid concomitant use; strong CYP3A4 inducer: avoid concomitant use; moderate CYP3A4 inducer: monitor effectiveness and escalate dose as needed. Exposure changes (clarithromycin AUC ↑3.5-fold; carbamazepine AUC ↓82%; efavirenz AUC ↓61%, PBPK-simulated) from Foundayo PI Section 12.3, Table 4.

Warfarin

Anticoagulant

Moderate — be aware

Common brand names

Coumadin · Jantoven

Clinical effect

Slowed gastric emptying may alter the absorption of oral warfarin, a narrow-therapeutic-index drug, and could affect INR. The Mounjaro and Zepbound labels name warfarin explicitly as a drug to monitor; in the semaglutide PK study there was no clinically significant change in S- or R-warfarin levels.

What to do

Patients on warfarin should have their INR monitored more frequently when starting or escalating a GLP-1 receptor agonist. Dose adjustment is rarely needed but should be discussed with the prescriber managing your anticoagulation.

Mechanism

GLP-1 receptor agonists slow gastric emptying. Warfarin absorption may be delayed but total bioavailability is generally preserved.

Source: Mounjaro PI Section 7.2; Zepbound PI Section 7.2 (monitor patients on oral medications with a narrow therapeutic index, e.g., warfarin); Wegovy PI Section 7.2 (consider increased clinical or laboratory monitoring for narrow-therapeutic-index oral medications) and Section 12.3 (no clinically significant PK change for S-warfarin or R-warfarin); Foundayo PI Section 7.3 (general oral-medication caution).

Oral contraceptives (combined and progestin-only)

Oral contraceptive

Moderate — be aware

Common brand names

Yasmin · Yaz · Loestrin · Lo Loestrin Fe · Microgestin · Sprintec · Tri-Sprintec · Ortho Tri-Cyclen · Necon · Junel · Mononessa · Camila · Errin · Slynd

Clinical effect

The tirzepatide labels (Mounjaro and Zepbound) carry an explicit FDA directive for oral hormonal contraceptives because tirzepatide's pharmacokinetic study showed reduced contraceptive exposure after the first dose. Foundayo (oral orforglipron) carries the same type of directive. Semaglutide is different: the Wegovy and Ozempic labels report NO clinically significant change in ethinyl estradiol or levonorgestrel pharmacokinetics, so semaglutide does not require backup contraception.

What to do

If you take oral birth control and start TIRZEPATIDE (Mounjaro or Zepbound) or FOUNDAYO, the FDA label directs you to switch to a non-oral method (IUD, implant, injection, patch, ring) OR add a barrier method. Tirzepatide: for 4 weeks after starting and 4 weeks after each dose increase. Foundayo: for 30 days after starting and 30 days after each dose increase. Semaglutide (Wegovy/Ozempic) does not carry this requirement, but always confirm your contraception plan with your prescriber.

Mechanism

Slowed gastric emptying can reduce or delay absorption of oral medications. For tirzepatide the effect on oral contraceptive exposure is documented and labeled (largest after the first dose, diminishing over time); for Foundayo it is labeled as a precaution; for semaglutide the labeled PK data show no clinically significant effect. Non-oral hormonal contraceptives are not affected.

Source: Mounjaro PI Section 7.2; Zepbound PI Section 7.2 (barrier/non-oral for 4 weeks after initiation and each escalation); Foundayo PI Section 7.3 (barrier/non-oral for 30 days after initiation and each escalation). Semaglutide: Wegovy/Ozempic PI Section 12.3 reports no clinically significant change in ethinyl estradiol/levonorgestrel PK. Tirzepatide PK (first 5 mg dose: ethinyl estradiol Cmax ↓59%, AUC ↓20%): Mounjaro/Zepbound PI Section 12.3.

Levothyroxine (thyroid hormone replacement)

Thyroid hormone

Moderate — be aware

Common brand names

Synthroid · Levoxyl · Tirosint · Unithroid

Clinical effect

Slowed gastric emptying may change levothyroxine absorption. With SEMAGLUTIDE TABLETS (Wegovy tablets, Rybelsus, Ozempic tablets) the label reports levothyroxine exposure rose 33% in a drug-interaction study, so thyroid levels can shift. The injectable GLP-1s have no levothyroxine-specific label finding, only the general oral-medication caution.

What to do

Tell your prescriber you take levothyroxine before starting any GLP-1, and expect a TSH check after starting or escalating. If you take a semaglutide tablet, the label says to take it on an empty stomach with up to 4 ounces of water and wait at least 30 minutes before other oral medications — since levothyroxine is also an empty-stomach pill, ask your prescriber or pharmacist how to sequence the two. Do not change your levothyroxine dose on your own.

Mechanism

Semaglutide delays gastric emptying, which can change how much and how fast oral drugs are absorbed. For semaglutide tablets, total thyroxine AUC rose 33% with a single 600 mcg levothyroxine dose (Cmax unchanged).

Source: Wegovy PI Section 7.2 (levothyroxine exposure increased 33% with the semaglutide tablet; consider increased monitoring for oral medications that require clinical monitoring), Section 12.3 (study detail), and Section 2.1 (tablet: wait at least 30 minutes before other oral medications); Rybelsus/Ozempic tablets PI Sections 2.1 and 7.2 (same). Injectables: Ozempic, Mounjaro, Zepbound PI Section 7.2; Foundayo PI Section 7.3 (general oral-medication caution).

Opioid analgesics

Opioid analgesic

Moderate — be aware

Common brand names

OxyContin · Percocet · Vicodin · tramadol · Norco · Dilaudid · morphine · fentanyl patch · codeine

Clinical effect

Both opioids and GLP-1 receptor agonists slow gut motility. Combined use additively raises the risk of ileus, severe constipation, and fecal impaction — events listed in Section 6.2 (Postmarketing Experience) of every FDA-approved GLP-1 label.

What to do

Use the lowest effective opioid dose. Increase fluid and fiber. Stop the GLP-1 and seek emergency care immediately for any of: abdominal distension, no stool or gas for >24 hours, persistent vomiting, severe constant abdominal pain.

Mechanism

Two separate motility-slowing mechanisms (opioid μ-receptor effects on enteric neurons + GLP-1 receptor agonism on enteric neurons) compound additively. Especially relevant during early titration when GLP-1 GI effects are highest.

Source: GLP-1 ileus / intestinal obstruction listed in Section 6.2 (Postmarketing Experience) of every FDA-approved GLP-1 label. No formal PK study of opioid + GLP-1 combination has been published; this is mechanism-based clinical guidance per ASA perioperative recommendations and the same FDA postmarketing signal.

Benzodiazepines (alprazolam, lorazepam)

Benzodiazepine

Moderate — be aware

Common brand names

Xanax · alprazolam · Ativan · lorazepam · Klonopin · clonazepam · Valium · diazepam · Restoril · temazepam

Clinical effect

Benzodiazepines distribute into adipose tissue. As body weight decreases on a GLP-1, the volume of distribution can shift, potentially raising effective plasma concentration at the same dose. A 2025 review reports lorazepam volume of distribution is about 1.7-fold lower in non-obese than in obese people.

What to do

Monitor for increased sedation, balance impairment, and morning grogginess — especially during the rapid-weight-loss phase (months 1-6). Discuss possible dose reduction with your prescriber if symptoms emerge. Do not adjust dose on your own.

Mechanism

Benzodiazepines are highly lipophilic. Reduced fat compartment with rapid weight loss → smaller distribution volume → higher relative plasma concentration at the same milligram dose.

Source: PMC12052016 (Drug Des Devel Ther 2025 review of GLP-1 receptor agonist pharmacokinetics and drug-drug interactions), which cites diazepam, lorazepam, and nitrazepam volume of distribution 3.2-, 1.7-, and 2.1-fold lower in non-obese participants. No GLP-1-cohort-specific PK study has been published; mechanism applies to any rapid-weight-loss context.

Acetaminophen (paracetamol)

Analgesic / antipyretic

Minor — generally safe

Common brand names

Tylenol · Panadol · FeverAll

Clinical effect

Slowed gastric emptying may delay the onset of acetaminophen, mostly after the first GLP-1 doses. Total exposure (AUC) is preserved.

What to do

No specific action needed. Acetaminophen will still work but may take slightly longer to relieve pain or fever. Take as you normally would.

Mechanism

GLP-1 receptor agonists slow gastric emptying, an effect largest after the first dose that diminishes with continued dosing. After a first 5 mg tirzepatide dose, acetaminophen peak concentration fell 50-55% and arrived about 1 hour later, with no meaningful effect by week 4-6; on Foundayo the first-dose drop in acetaminophen peak was 28%.

Source: Mounjaro PI Section 12.3; Zepbound PI Section 12.3; Foundayo PI Section 12.3 (acetaminophen gastric-emptying probe data); Wegovy PI Section 7.2 (Oral Medications, general caution)

Metformin

Biguanide (oral diabetes medication)

Minor — generally safe

Common brand names

Glucophage · Glumetza · Fortamet · Riomet

Clinical effect

Generally well tolerated together. Both drugs share GI side effects (nausea, diarrhea), which may be additive in the first weeks of GLP-1 therapy.

What to do

Continue metformin as prescribed. Be aware that nausea and diarrhea may temporarily be worse during the GLP-1 dose ramp. No dose adjustment of either drug is typically needed.

Mechanism

Independent mechanisms (metformin: AMPK activation, decreased hepatic glucose production; GLP-1: enhanced glucose-dependent insulin secretion). Both produce GI side effects independently.

Source: Common combination, no specific FDA label warning

Statins (HMG-CoA reductase inhibitors)

Cholesterol medication

Minor — generally safe

Common brand names

Lipitor · atorvastatin · Crestor · rosuvastatin · Zocor · simvastatin · Pravachol · pravastatin · Mevacor · lovastatin

Clinical effect

For the injectable GLP-1s (semaglutide, tirzepatide) there is no clinically significant interaction — slowed gastric emptying may slightly delay statin absorption but total exposure and clinical effect are preserved (the Wegovy label reports no clinically significant change in rosuvastatin PK, and the Ozempic label none for atorvastatin). FOUNDAYO (orforglipron) is the exception: because Foundayo raises simvastatin exposure, the label caps the simvastatin dose.

What to do

If you take an injectable GLP-1, continue statin therapy as prescribed — no timing changes needed. If you take FOUNDAYO, do not exceed simvastatin 20 mg once daily; other statins are not restricted. Confirm your statin dose with your prescriber when starting Foundayo.

Mechanism

Injectable GLP-1 statin absorption is not meaningfully affected by slowed gastric emptying. Foundayo raised exposure of simvastatin acid (the active form) about two-fold, even when the doses were taken 2 hours apart, so the label limits the simvastatin dose.

Source: Injectables: Wegovy PI Section 12.3 (no clinically significant change in rosuvastatin PK); Ozempic PI Section 12.3 (no clinically relevant change in atorvastatin PK); no specific label warning for other statins. Foundayo PI Section 7.2 — do not exceed simvastatin 20 mg once daily when used concomitantly with Foundayo; Section 12.3 — simvastatin acid ↑2- to 2.5-fold whether co-administered or staggered by 2 hours.

ACE inhibitors and ARBs (blood pressure medications)

Blood pressure medication

Minor — generally safe

Common brand names

Lisinopril · Zestril · Prinivil · losartan · Cozaar · valsartan · Diovan · irbesartan · Avapro · olmesartan · Benicar

Clinical effect

No specific interaction. GLP-1-induced weight loss may modestly lower blood pressure, which can be additive with antihypertensive therapy.

What to do

Continue blood pressure medications as prescribed. Monitor for symptomatic low blood pressure (lightheadedness on standing) as you lose weight, since you may need a dose reduction over time.

Mechanism

Weight loss reduces blood pressure independently. Combined with antihypertensive therapy this can occasionally produce hypotension.

Source: Common combination, no specific FDA label warning

SSRIs and SNRIs (antidepressants)

Antidepressant

Minor — generally safe

Common brand names

Lexapro · escitalopram · Zoloft · sertraline · Prozac · fluoxetine · Paxil · paroxetine · Cymbalta · duloxetine · Effexor · venlafaxine · Wellbutrin · bupropion

Clinical effect

No specific drug interaction. The 2024 EMA and FDA reviews of GLP-1 receptor agonists found no causal association with depression or suicidal ideation in randomized trials.

What to do

Continue antidepressant therapy as prescribed. If you have a history of depression, monitor mood actively in the first 8-12 weeks of GLP-1 therapy and discuss any changes with both your prescriber and mental health provider.

Mechanism

Independent mechanisms with no documented pharmacokinetic interaction.

Source: EMA PRAC review April 2024; FDA evaluation 2024 — no signal of psychiatric harm in RCTs. The Wegovy and Zepbound labels removed their Suicidal Behavior and Ideation warning in 02/2026 (Recent Major Changes).

PPIs and H2 blockers (acid reflux medications)

Acid suppression

Minor — generally safe

Common brand names

Prilosec · omeprazole · Nexium · esomeprazole · Protonix · pantoprazole · Pepcid · famotidine · Zantac

Clinical effect

No specific drug interaction. May actually be beneficial — GLP-1 receptor agonists can produce or worsen acid reflux, and PPIs/H2 blockers manage it.

What to do

Continue or initiate as needed for reflux symptoms. Discuss persistent or severe reflux with your prescriber.

Mechanism

GLP-1-induced slowed gastric emptying can worsen GERD; acid suppression manages the symptom.

Source: No specific FDA label warning

NSAIDs (ibuprofen, naproxen, celecoxib)

Non-steroidal anti-inflammatory drug (NSAID)

Minor — generally safe

Common brand names

Advil · Motrin · ibuprofen · Aleve · naproxen · Celebrex · celecoxib · Mobic · meloxicam

Clinical effect

GLP-1-induced gastric emptying delay can mildly delay NSAID absorption (later Tmax, lower Cmax) but total daily exposure is generally preserved. Clinically usually not significant for episodic pain dosing.

What to do

Take as prescribed. Watch for unusual NSAID-related GI side effects, which can compound the GLP-1 GI burden during titration. If you need an NSAID for ongoing pain, discuss the timing and dose with your prescriber.

Mechanism

Delayed gastric emptying alters absorption kinetics of orally administered NSAIDs without reducing total bioavailability.

Source: FDA Section 7.2 of every GLP-1 label, Section 7.3 on Foundayo (general delayed-gastric-emptying caution). Hooper et al, Pharmacotherapy 2025 (PMID 39989027) PBPK modeling supports preserved AUC. No GLP-1-cohort-specific PK study of NSAIDs has been published; mechanism-plausible only.

Oral antibiotics

Oral antibiotic

Minor — generally safe

Common brand names

amoxicillin · Augmentin · azithromycin · Z-Pak · doxycycline · ciprofloxacin · Cipro · clindamycin · cephalexin · Keflex

Clinical effect

GLP-1-induced gastric emptying delay can affect oral antibiotic absorption rates. Total exposure is generally preserved but onset of action may be delayed for some agents.

What to do

Take as prescribed and complete the full course. If severe nausea or vomiting on the GLP-1 prevents you from keeping antibiotic doses down, contact your prescriber promptly — antibiotic underdosing risks treatment failure and antimicrobial resistance.

Mechanism

Class-level FDA Section 7.2 (Foundayo: Section 7.3) caution for any oral medication co-administered with a drug that delays gastric emptying. No antibiotic-specific PK study has been published.

Source: FDA Section 7.2 of every GLP-1 label, Section 7.3 on Foundayo (general oral-medication caution). No formal PK study of any specific antibiotic + GLP-1 combination has been published; class-level mechanism-based guidance only.

Atypical antipsychotics (olanzapine, quetiapine)

Atypical antipsychotic

Minor — generally safe

Common brand names

Zyprexa · olanzapine · Seroquel · quetiapine · Risperdal · risperidone · Abilify · aripiprazole · Clozaril · clozapine

Clinical effect

GLP-1 receptor agonists effectively counteract antipsychotic-induced weight gain in patients on long-term antipsychotic therapy. Multiple systematic reviews support this combination as beneficial; no clinically significant pharmacokinetic interaction has been documented.

What to do

Continue both medications under prescriber supervision. The GLP-1 can mitigate antipsychotic-driven weight gain without reducing antipsychotic efficacy. Coordinate with the prescribing psychiatrist or PCP.

Mechanism

GLP-1 effects on appetite and gastric emptying counteract the appetite-stimulating and weight-gain effects of atypical antipsychotics. The two work on different physiological pathways without pharmacokinetic interference.

Source: Systematic reviews PMC10265718 + PMC12528064 on GLP-1 receptor agonists in antipsychotic-induced weight gain. No clinically significant DDI documented; mechanism-supported beneficial combination.

How to read the severity tiers

  • Contraindicated — Do not combine. The combination is either explicitly contraindicated by the FDA label or universally recognized as unsafe (e.g., two GLP-1 receptor agonists at the same time).
  • Serious — Combination is allowed but requires close monitoring or proactive dose adjustment of one of the drugs. The classic example is insulin or a sulfonylurea — both can cause hypoglycemia, and adding a GLP-1 on top requires reducing the dose of the existing diabetes medication before the first GLP-1 dose.
  • Moderate — Be aware. The interaction is real but usually does not require dose adjustment. Often involves slowed gastric emptying affecting the absorption rate (not total bioavailability) of an oral medication. Examples: warfarin, levothyroxine, oral contraceptives.
  • Minor — Generally no action needed. Either no documented interaction or the effect is clinically irrelevant (e.g., a 30-60 minute delay in acetaminophen onset).

Why GLP-1s have so many gastric-emptying interactions

GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action — that's a major contributor to the satiety effect that produces weight loss. The same mechanism delays the absorption of orally administered medications, most of all after the first doses: after a first tirzepatide dose, the acetaminophen peak arrived about an hour later, and the effect faded with continued dosing. For most drugs, total bioavailability (the area under the curve, AUC) is preserved, so the drug still works, but it may take slightly longer to reach peak concentration. Semaglutide tablets are an exception worth knowing: levothyroxine exposure rose 33% when taken with them. The clinical significance is small for most medications and meaningful only for drugs with a narrow therapeutic window or a time-sensitive onset.

Hypoglycemia risk with insulin and sulfonylureas

The most clinically important GLP-1 interaction is the additive hypoglycemia risk when combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride). GLP-1s enhance glucose-dependent insulin secretion — meaning they only push insulin when blood sugar is elevated — but adding insulin or a sulfonylurea on top can produce dangerous lows. Every GLP-1 label tells prescribers to consider reducing the insulin or sulfonylurea dose when the GLP-1 is started; the labels do not set a fixed percentage, so your prescriber decides how much. This should be discussed with your prescriber in advance, not after the fact. Our diabetes medication interactions cheat sheet lays these combinations out by drug class.

Oral contraceptives: tirzepatide and Foundayo carry a labeled warning

The FDA labels treat oral birth control differently depending on the GLP-1. Tirzepatide (Mounjaro and Zepbound) carries an explicit Section 7 directive: switch to a non-oral method (IUD, implant, injection, patch, or ring) or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase. Foundayo (orforglipron, the oral GLP-1) carries the same type of directive but for 30 days after starting and 30 days after each dose increase. Semaglutide (Wegovy and Ozempic) is the exception — its label reports no clinically significant change in oral contraceptive (ethinyl estradiol/levonorgestrel) levels, so it does not require backup contraception. Non-oral hormonal methods are not affected by any GLP-1. If you take oral birth control and are starting tirzepatide or Foundayo, discuss a backup strategy with your prescriber before your first dose. Why the labels split this way is explained in our birth control and GLP-1 clarifier.

What this tool is NOT

This is an educational lookup tool, not a clinical decision support system. It is not a substitute for your prescriber, your pharmacist, or a real-time interaction checker built into electronic health records. The database covers the highest-frequency clinically meaningful interactions but is not exhaustive. Always tell every prescriber and pharmacist about every medication you take, including over-the-counter products and supplements, and confirm any specific interaction with them before starting or stopping anything.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information, Sections 1, 2, 7 and 12.3 (revised 06/2026). FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Sections 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  3. 3.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets — US Prescribing Information, Sections 2.1 and 7. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Sections 1, 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Sections 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Sections 1, 2.2, 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  7. 7.European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). GLP-1 receptor agonists — review of psychiatric adverse events. PRAC Assessment Report. EMA. 2024. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024

Related tools and research

Important disclaimer

This tool is for educational purposes only and does not constitute medical advice. Drug interactions are highly individual and depend on dose, timing, and your overall medication list. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations. Always consult your prescribing clinician and pharmacist before combining any medication with a GLP-1 receptor agonist.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

From $289/4 wks (billed per 4 weeks)

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo (starting dose)

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $99/mo

Get started →